Does Rallies show Form 4 insider transactions for BDTX?

Yes. Rallies tracks BDTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BDTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BDTX. It does not provide personalized investment advice.

BDTX (Black Diamond Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Black Diamond Therapeutics, Inc. Common Stock (BDTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BDTX trades at $3.66 with a market cap of $147.84M and a P/E ratio of 8.81. BDTX moved +20.00% today. Year to date, BDTX is +40.08%; over the trailing twelve months it is +65.90%. Its 52-week range spans $1.20 to $4.94. Analyst consensus is strong buy with an average price target of $10.25. Rallies surfaces BDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BDTX stock inside the company?

Recent BDTX insider activity includes BIOTECH GROWTH N V sold 1.00M, BIOTECH GROWTH N V sold 300.00K, BIOTECH GROWTH N V sold 1.00M, BIOTECH GROWTH N V sold 2.00M, and BIOTECH GROWTH N V sold 400.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BDTX Key Metrics

Key financial metrics for BDTX
Metric	Value
Price	$3.66
Market Cap	$147.84M
P/E Ratio	8.81
EPS	$0.39
Dividend Yield	0.00%
52-Week High	$4.94
52-Week Low	$1.20
Volume	3.11K
Avg Volume	0
Revenue (TTM)	$70.00M
Net Income	$22.37M
Gross Margin	0.00%

Recent BDTX Insider Trades

BIOTECH GROWTH N V sold 1.00M (~$2.07M) on Mar 19, 2025.
BIOTECH GROWTH N V sold 300.00K (~$582.90K) on Mar 19, 2025.
BIOTECH GROWTH N V sold 1.00M (~$2.31M) on Mar 19, 2025.
BIOTECH GROWTH N V sold 2.00M (~$4.00M) on Mar 19, 2025.
BIOTECH GROWTH N V sold 400.00K (~$837.16K) on Mar 19, 2025.

Latest BDTX News

Black Diamond Reports $9M Q1 Loss, $118M Cash and First EGFRvIII+ GBM Patient Dosed — May 7, 2026
Black Diamond Ends 2025 with $128.7M Cash, Sets Q2 2026 Phase 2 NSCLC and GBM Trials — Mar 16, 2026
Black Diamond to Present NSCLC PFS Data After 60% ORR, 93% DCR — Mar 6, 2026

BDTX Analyst Consensus

5 analysts cover BDTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.25.

Common questions about BDTX

Who is trading BDTX stock inside the company?: Recent BDTX insider activity includes BIOTECH GROWTH N V sold 1.00M, BIOTECH GROWTH N V sold 300.00K, BIOTECH GROWTH N V sold 1.00M, BIOTECH GROWTH N V sold 2.00M, and BIOTECH GROWTH N V sold 400.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BDTX?: Yes. Rallies tracks BDTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BDTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BDTX. It does not provide personalized investment advice.